Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand
PharmacoEconomics - Open · 2025-01 · 9 (1) · 69-81
DOI: 10.1007/s41669-024-00526-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift PharmacoEconomics - Open, online erschienen am 22.09.2024. Verfasst von Tanawan Kongmalai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bill and Melinda Gates Foundation, Medicine Regulations Division of the Food and Drug Administrations, Ministry of Public Health, Thailand.
Themen: Diabetes mellitus, Herzinsuffizienz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.
- Siriraj Health Policy Unit, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Social Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
- Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand. Varalaksi@gmail.com.
Förderung
- Bill and Melinda Gates Foundation
- Medicine Regulations Division of the Food and Drug Administrations, Ministry of Public Health, Thailand
Zitieren
APA
Kongmalai, T., Prawjaeng, J., Hadnorntun, P., Leelahavarong, P., Chaikledkaew, U., Thakkinstian, A., & Srinonprasert, V. (2025). Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand. PharmacoEconomics - Open, 9(1), 69-81. https://doi.org/10.1007/s41669-024-00526-2
Vancouver
Kongmalai T, Prawjaeng J, Hadnorntun P, Leelahavarong P, Chaikledkaew U, Thakkinstian A, et al. Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand. PharmacoEconomics - Open. 2025;9(1):69-81. doi:10.1007/s41669-024-00526-2
BibTeX
@article{Kongmalai2025,
author = {Kongmalai, Tanawan and Prawjaeng, Juthamas and Hadnorntun, Phorntida and Leelahavarong, Pattara and Chaikledkaew, Usa and Thakkinstian, Ammarin and Srinonprasert, Varalak},
title = {Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand},
journal = {PharmacoEconomics - Open},
year = {2025},
volume = {9},
number = {1},
pages = {69--81},
doi = {10.1007/s41669-024-00526-2}
}
EUVIMED